Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04026178 · ClinicalTrials.gov registry record · Phase 4
Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy
A Phase 4 study, sponsored by Aegerion Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT04026178 is a Phase 4 study that has completed, run by Aegerion Pharmaceuticals. The registered enrollment target is 11 participants.
The verdict
NCT04026178, a Phase 4 study, has completed, sponsored by Aegerion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
MYALEPT™ (metreleptin) has been approved as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy (MYALEPT Prescribing Information). This study is a multicenter, open-label, Phase 4 trial to provide an assessment of the immunogenicity associated with metreleptin and of any major potential risks due to development of antibodies to metreleptin. The study is being conducted to comply with a postmarketing requirement.
Interventions
- DRUG Metreleptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-11-14 |
| Est. Completion | 2024-10-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04026178
The ClinicalTrials.gov registry entry for NCT04026178 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aegerion Pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Metreleptin is the first listed.
NCT04026178 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04026178 about?
NCT04026178 is a clinical study titled "Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy". MYALEPT™ (metreleptin) has been approved as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy (MYALEPT Prescribing Information). This study is a multicenter, open-label, Phase 4 trial to provide...
What is the current status of trial NCT04026178?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2018-11-14. Estimated completion is 2024-10-31.
What interventions are being tested in trial NCT04026178?
The interventions under investigation include: Metreleptin (DRUG).
Who is sponsoring clinical trial NCT04026178?
This trial is sponsored by Aegerion Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.